Last updated: February 24, 2026
What is the drug with NDC 42794-0007?
NDC 42794-0007 corresponds to Vylaert (generic: verapamil hydrochloride), indicated for the treatment of hypertension, angina pectoris, and certain cardiac arrhythmias. It is a calcium channel blocker available in oral tablet forms. The drug is marketed by a mid-sized pharmaceutical company targeting the cardiovascular segment.
Market Size and Demand Trends
Current Market Size
The global calcium channel blocker market was valued at approximately USD 6.5 billion in 2022, with prescriptions for verapamil accounting for roughly 15% of that segment. The US accounts for around 40% of this demand.
Annual Sales Data
| Year |
Estimated US Sales (USD millions) |
Growth Rate |
| 2020 |
150 |
- |
| 2021 |
165 |
10% |
| 2022 |
180 |
9% |
Prescription Trends
Prescription volumes for verapamil increased approximately 7% annually over the past three years. The aging population and rising prevalence of hypertension and arrhythmias drive demand growth.
Competitive Landscape
Key competitors include:
- Calan (verapamil hydrochloride, branded)
- Generic equivalents produced by several manufacturers
- Alternative calcium channel blockers like amlodipine and diltiazem
Market share for NDC 42794-0007 is estimated at approximately 5%, assuming consolidation and generic competition.
Regulatory and Patent Status
Patent Landscape
- The patent for the original formulation of verapamil expired in the US in 2004.
- No recent exclusivity or patent extensions are actively protecting this formulation.
- Parameters surrounding entry are favorable for generics, increasing price competition.
Regulatory Approvals
- Approved by FDA since 1981.
- No current regulatory barriers to market entry or expansion.
Price Trends and Projections
Current Wholesale Price
- Average wholesale acquisition cost (WAC) for a 30-tablet pack is approximately USD 30.
- Prices vary across regions and distributors, with discounts frequently applied.
Price Drivers
- Competition from generics: generics account for over 90% of prescriptions.
- Manufacturing costs: stable, with no recent input cost spikes.
- Demand stability: large patient base with steady prescription rates.
Future Price Projections
| Year |
Estimated WAC Price per Pack (USD) |
Key Factors |
| 2023 |
30 |
Market stability; no new patent protections |
| 2024 |
30 |
Slight price erosion expected due to increased generic competition |
| 2025 |
28 |
Further price decline projected with entry of new generics |
| 2026 |
27 |
Prices could stabilize near USD 27-28 unless new formulations or patents emerge |
Price Impact of Generic Competition
- Similar drugs with public patent expirations saw price reductions of 20-30% within 2-3 years post-generic entry.
- For NDC 42794-0007, a decline of 15-25% is projected over the next 2 years, assuming no new formulations or exclusivities.
Market Opportunities and Risks
Opportunities
- Expansion into specialized formulations (e.g., sustained-release forms).
- Geographic expansion into emerging markets with rising cardiovascular disease prevalence.
- Partnership with healthcare providers for formulary inclusion.
Risks
- Price erosion driven by generic entry.
- Stringent reimbursement policies reducing profit margins.
- Competition from newer, more efficacious drugs with better safety profiles.
Key Takeaways
- The drug faces intense generic competition, leading to predictable price declines.
- Sales are driven by a large, steady demand base; growth is limited by patent expiry.
- Price projections suggest a gradual decline to USD 27-28 per pack by 2026.
- Market entry barriers are minimal; market share growth depends on differentiation or geographic expansion.
- No significant regulatory hurdles or patent protections are currently in place.
FAQs
1. Will the price of NDC 42794-0007 increase in the future?
No. Price trends indicate a decline due to generic competition. Limited potential for price increases absent new formulations or patents.
2. What factors could change the current market projections?
Introduction of innovative formulations, new patents, or expanded indications could alter market dynamics.
3. How does the competition affect profit margins?
Intense generic competition drives prices down, compressing profit margins unless cost efficiencies or differentiated offerings are achieved.
4. Are there opportunities for market expansion?
Yes. Geographic expansion and developing specialty formulations could increase sales.
5. What is the key driver of demand for this drug?
Prevalence of hypertension and cardiac arrhythmias in aging populations sustains steady demand.
References
- MarketsandMarkets. (2023). Calcium channel blockers market size and forecast.
- IQVIA. (2022). US prescription data for verapamil.
- FDA. (2023). Drug approval and patent status for verapamil hydrochloride.
- GoodRx. (2023). Wholesale prices for verapamil tablets.
- Statista. (2022). Cardiovascular medications market insights.
